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Summary This study describes the efficacy and toxicity of a combination regimen consisting of cyclopho-
sphamide, vincristine (oncovin) and carboplatin (COC) for advanced seminoma on an outpatient basis.
Twenty-seven patients (mean age 43 years, range 28-63 years) were classified as stage IIC (n=5), stage IID
(n= 12), stage III (n=9) or stage IV (n= 1). Six had been treated with prior radiotherapy; elevated f,-HCG and
elevated LDH serum levels were observed in 15 and 25 patients respectively. Patients were treated with four
cycles of 750 mg m-2 cyclophosphamide intravenously (i.v.), 1.4 mg m-2 vincristine i.v. (maximum 2 mg) and
carboplatin adjusted to creatinine clearance. Cycles were given at 3 week intervals. The median dose of
carboplatin administered was 400 mg m 2 (range 300-450 mg m-2). Six patients [22%; 95% confidence
interval (CI), 6-38%] achieved a complete response (CR), 19 (70%; 95% CI, 51-88%) a partial response and
two (8%; 95% CI, 0-18%) showed only a response in tumour markers but not a reduction of retroperitoneal
mass (NR). Post-chemotherapeutic masses were not removed surgically or irradiated. After a median follow-up
of 26 months (range 5-69 months), two patients have died, one from cardiac arrest 2 years after achieving CR,
the other with relapsed seminoma 5 months after therapy. None of the other patients relapsed. Main toxicity
was haematological, with 22 patients (81%) experiencing thrombocytopenia WHO grade III/IV and 27 (I00/7)
leucocytopenia WHO grade III/IV, requiring dose reduction in five patients. Seven patients experienced
granulocytopenic fever. Non-haematological toxicity was rare. Peripheral neuropathy grade I was observed in
four patients and grade III in one. Haemorrhagic cystitis occurred once. In conclusion, despite considerable
haematological toxicity, COC is feasible on an outpatient basis, even after prior radiotherapy, and is an
effective regimen for advanced seminoma with only 1/27 treatment failures after a median follow-up of 26
months.
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Seminoma is a tumour that is highly sensitive to radio-
therapy. Therefore, low-stage seminoma (Royal Marsden
classification stage IIA/IIB) can be successfully treated with
radiotherapy (Thomas et al., 1982; Fossa et al., 1989).
Because of high relapse rates after radiotherapy in more
advanced stages (Thomas et al., 1982), such patients are
commonly treated primarily with chemotherapy. Chemother-
apeutic regimens used have been based on experiences
obtained in the treatment of non-seminomas. Cisplatin-
based combination chemotherapy has been shown to be
very effective in the treatment of seminomas, and the
combination consisting of etoposide and cisplatin with or
without bleomycin can be considered as standard therapy
nowadays (Mencel et al., 1994; Williams et al., 1991).
Unfortunately, cisplatin-based regimens are characterised by
toxic side-effects such as renal damage, neurotoxicity and
ototoxicity and require hospitalisation. Carboplatin is a
cisplatin analogue that lacks many of the side-effects of
cisplatin and can be administered on an outpatient basis
(Calvert et al., 1985). Used as a single agent, carboplatin is
active against seminoma (Schmoll et al., 1993; Horwich et al.,
1989), but many patients relapse (Horwich et al., 1992).
Cyclophosphamide (Logothesis et al., 1987; Wettlaufer et
al., 1984) and vincristine (Fossa et al., 1995; Wettlaufer et al.,
1984) are agents which have also been successfully used in
combination with other drugs against testicular cancer.
This study describes the efficacy and toxicity of a
combination regimen for advanced seminoma consisting of
carboplatin, vincristine (oncovin) and cyclophosphamide
(COC) administered on an outpatient basis.
Patients and methods
Between January 1989 and April 1995, 27 patients with
histologically proven advanced seminoma (> stage IIC) were
entered in this study. All patients were thoroughly evaluated
including measurement of fl-human chorionic gonadotrophin
(P-HCG), a-fetoprotein (axFP) and lactate dehydrogenase
(LDH). Before treatment, patients were staged according to
the Royal Marsden classification (Peckham et al., 1979) by
physical examination and computed tomography (CT) of
abdomen and chest. Before and during each cycle patients
were physically examined, accompanied by determination of
haemoglobin, white blood count (WBC), platelets, creatinine
clearance, liver function and tumour markers (f3-HCG, aFP
and LDH).
Patients were treated with four cycles of COC given at 3-
week intervals. Chemotherapy consisted of 750 mg m-2
cyclophosphamide i.v., 1.4 mg m-2 vincristine i.v. (max-
imum 2 mg) and carboplatin i.v. adjusted before each cycle to
the creatinine clearance. At creatinine clearance below 100,
between 100 and 120, between 120 and 140, or above 140 ml
min-', carboplatin doses administered were 300, 350, 400 or
450 mg m-2 respectively. The first cycle was given clinically,
the other cycles were administered on an outpatient basis.
Within 4 weeks after administration of the last cycle,
evaluation of response was performed by determination of
tumour markers and CT scanning of previous abnormal
lesions. Complete response (CR) was defined as complete
disappearance of known sites of disease and normalisation of
tumour markers. A more than 50% reduction of the sum of
the products of the longest diameter and its perpendicular for
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all known measurable lesions was defined as partial response
(PR). A no response (NR) was featured by a less than 50%
reduction of the sum of the products of the longest diameter
and its perpendicular.
After completion of chemotherapy, residual masses were
not removed surgically nor irradiated and patients were
followed by close observation. CT scanning during follow-up
was only performed if indicated.
Toxicity was evaluated in all patients and scored according
to the WHO criteria (WHO, 1978). Granulocytopenic fever
was defined as temperature >38°C and WBC <2 x109 1-'.
Postponement of a cycle was performed if the number of
thrombocytes was below 75 x 109 1` just before administra-
tion. In case of neuropathy WHO grade III/IV vincristine
was stopped. A 10% dose reduction of carboplatin was
carried out ifpatients received transfusion ofthrombocytes in
the previous cycle.
To analyse differences between groups, X2 was used. Only
P-values<0.05 were considered significant.
The study was approved by the medical ethics committee




Patient characteristics at entry of the study are depicted in
Table I. Two patients presented with an extragonadal
seminoma, all other patients had a testicular seminoma. Six
patients received prior radiotherapy on the abdomen for
stage I or IIA-IIB seminoma (mean total doses 31 Gy, range
25-38 Gy) but relapsed after an initial response.
None of the patients had an elevated acFP serum level
(normal<5 jg [1). An elevated LDH serum level (nor-
mal<235 IU l-l) was observed in 25 patients. Mean value of
the patients with an elevated LDH level was 928 IU 1`
(range 242-3665). Fifteen patients had an elevated ,B-HCG
serum level (normal<2 jg 1-') with a mean elevated level of
26.3 pg l-1 (range 3-135).
Response to treatment
Response to chemotherapy is shown in Table II. Six patients
(22%; 95% confidence interval (CI), 6-38%) achieved a CR,
19 (70%; 95% CI, 51-88%) a PR and two patients (8%;
95% CI, 0-18%) showed NR. Of the 21 patients with a
Table I Patients' characteristics
No. of patients 27








Elevated f =HCG 15
Elevated LDH 25
post-chemotherapeutic mass (19 PR and 2 NR), 11 patients
had a residual mass larger than 3 cm.
After a median follow-up of 26 months (range 5-69
months), two patients have died. Two years after obtaining a
CR, one patient, 44 years old, died from a cardiac arrest.
This patient had slightly elevated cholesterol serum levels and
a family history of cardiac disease. The other patient had a
slightly elevated LDH serum level and an increasing residual
mass 4 months after obtaining a NR. Complete surgical
removal of the mass appeared to be impossible during
laparotomy. Histology revealed necrosis and viable seminoma
cells. Five months after completion of chemotherapy, this
patient died from progressive disease. None of the other
patients relapsed, so after a median follow-up of 26 months,
25 patients (93%; 95% CI, 83-100%) are alive and show no
evidence of active disease. The median observation period in
patients with a residual mass larger than 3 cm is 25 months
(range 4-59 months).
Toxicity of treatment
All patients received four cycles, so in total 108 cycles were
given. The median dose of carboplatin administered was
400 mg m-2 (range 300-450 mg m-2).
Because of haematological toxicity, a 10% dose reduction
of carboplatin was carried out in five cycles (5%) in four
patients. Vincristine was not administered in one patient in
the last cycle because of neuropathy. Postponement of cycles
was performed in 14 cycles (13%) in ten patients. Mean
postponement was 4.5 days (range 2-7 days).
Toxicity is outlined in Table III. Main toxicity was
Table H Tumour responses and follow-up
Response Follow-up
No. CR PR NR Relapsed Deaths
All patients 27 6 19 2 1 2
Previous radiotherapy 6 5 1 0 0 0
Stage
IIC 5 1 4 0 0 0
IID 12 1 9 2 1 2
III 9 4 5 0 0 0
IV 1 0 1 0 0 0
Table III Toxicity
No. ofpatients Cycles (%)
(%)
Thrombocytopenia (WHO grade III/IV) 22 (81) 57 (53)
Thrombocyte transfusion 11 (41) 18 (17)
Leucocytopenia (WHO grade III/IV) 27 (100) 85 (79)
Granulocytopenic fever 7 (26) 8 (7)
Neuropathy (WHO grade III/IV) 1 (4) 1(1)cOC Bob d _it u,c-d suuu sm
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haematological. Thrombocytopenia WHO grade IHI/TV was
observed in 57 cycles (53%) in 22 patients requiring
tansfuion of thrombocytes in 18 cycles (17%) in 11
patients. No bleeding episodes occurred. Leucocytopenia
grade II/IV was encountered in 85 cycles (79%) in 27
patients. Granulocytopenic fever occurred in eight cycles
(7%) in seven patients. These patients were admitted and
intensively treated with antibiotics. Two patients received
granulocyte colony-stimulating factor (G-CSF). In patients
receiving prior radiotherapy, occurrence ofthrombocytopenia
or leucocytopenia WHO grade III/IV was not different
compared with the other patients.
Non-haematological toxicity was rare. Four patients
experienced neuropathy grade I and one patient grade Ill.
Haemorrhagic cystitis was observed in one patient.
Dissai
Combination chemotherapy is the treatment of choice for
patients presenting with advanced seminoma or relapsing
after previous radiotherapy. The regimens used have been
based on results obtained in the treatment of non-seminoma
and consequently cisplatin-based regimens have become
standard. Mencel et al. (1994) compared different platinum-
based chemotherapeutic combinations and concluded that
four cycles with etoposide and cisplatin is the most effective
therapy leading to a response rate of approximately 95%.
However, cisplatin-containing regimens are feared for their
induction of auditory, neural or renal toxicity and usually
require some form of hospitalisation.
Used at standard doses, carboplatin has several advan-
tages over cisplatin with the most important feature being its
lack of nephrotoxicity which makes hydration and hospita-
lisation unnecessary (Calvert et al., 1985). Carboplatin used
as a single agent has been shown to be active against
seminoma resulting in a response level similar to that
obtained with cisplatin-based combinations (Horwich et al.
1989, 1992; Schmoll et al., 1993). However, Horwich et al.
(1992) observed that 23% of the patients relapsed after a
median follow-up of 3 years, a recurrence rate too high for
this type of cancer. Therefore, we developed a carboplatin-
containing multidrug regimen which would hopefully lead to
a lower relapse rate.
Cyclophosphamide has been shown to be effective against
seminoma as a single agent (Schneider et al., 1964) and in
combination with cisplatin (Logothetis et al., 1987).
Wettlaufer et al. (1984) were the first to use vincristine in
the treatment of testicular cancer and treated seminoma
patients with a combination ofvincristine, cyclophosphamide
and cisplatin followed by radiotherapy for residual lesions. In
this study of 12 patients, these authors report 92% to be
without evidence of disease after a median follow-up of 24
months. Recently, Fossa et al. (1995) modified Wettlaufer's
regimen by substituting cyclophosphamide for ifosphamide
yielding an effective regimen with a 3-year survival of 90%.
This combination was however relatively toxic particularly
with myelosuppression. Although remaining controversial,
ifosphamide has been claimed to have several advantages
over cyclophosphamide (Kamen et al., 1995). Recently,
Amato et al. (1995) treated advanced seminoma with a
combination of carboplatin and cyclophosphamide resulting
in 91% of the patients free of disease after a median follow-
up of 35 months. However, compared with ifosphamide,
cyclophosphamide has the merit of being suitable for
administration on an outpatient basis.
In this study, we also modified the regimen as designed by
Wettlaufer et al. (1984) by replacing cisplatin with
carboplatin (COC). COC resulted in 93% of the patients
free of disease after a median follow-up of 26 months, a
figure equivalent to that achieved with other multidrug
regimens (Fossa et al., 1995; Gietema et al., 1991; Loehrer
et al., 1987; Mencel et al., 1994; Amato et al., 1995).
Toxicity of COC was mainly myelosuppression with 100%
of the patients experiencing leucocytopenia grade m/Iv and
81% thrombocytopenia grade HI/IV. This toxicity is
comparable with studies using similar doses of carboplatin
and cyclophosphamide for ovarian carcinoma (De Vries et
al., 1991; Biesma et al., 1992). However, this kind of toxicity
may be prevented partly by the addition of growth factors
such as IL-3 (Biesma et al., 1992; Veldhuis et al., 1995) or
GM-CSF (De Vries et al., 1991).
Residual mass after chemotherapy for seminoma is a
common phenomenon, but its management remains con-
troversial. Several options have been suggested such as
surgical removal (Motzer et al., 1987), radiotherapy (FossA
et al., 1987), biopsy to detect viable tumour cells or
observation (Schultz et al., 1989). Addition of surgery or
radiotherapy, especially of large residual masses, would add
to the overall toxicity of the treatment and therefore in this
study patients were followed by close observation.
The only treatment failure in this study relapsed in a
residual mass of 10 cm. Although large lesions have been
described to be at increased risk, this risk does not seem to be
high (1/11) after the regimen described here.
Shrinkage of post-chemotherapeutic mass is a phenomen-
on known to occur often in seminoma (Fossa et al., 1995).
However, we did not perform CT scans during follow-up, so
in this study it is not possible to evaluate whether lesions
observed directly after therapy disappeared in time.
Although the number of patients treated is small and the
follow-up relatively short, it can be concluded that COC is an
effective regimen for advanced seminoma resulting in a
response level similar to that achieved by others. Besides
that, its main toxicity, myelosuppression, may be partly
prevented by the addition ofgrowth factors, the advantage of
COC over other regimens is its feasibility to treat on an
outpatient basis.
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